DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE; 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride; Acetylcysteine; Adenosine; Air; Alcohol; Antiarrhythmic drugs; Atorvastatin; BNP; BNP blood sample test; Behavioral: Lifestyle; Bluefish; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CK-3773274; CK-3773274 (10 - 30 mg); CK-3773274 (5 - 15 mg); CK-3773274 - Granules in Capsule; CK-3773274 - Tablets; CT-G20; Candesartan; Carnitine; Cufence; Cyclosporine; Cyclosporine A; Device: Insertable cardiac monitor; Device: Magnetic resonance imaging (MRI) with gadolinium enhancement; Device: Magnetic resonance imaging (MRI) without gadolinium enhancement; Device: Use of bioanalytical assay to monitor plasma levels of perhexiline; Diagnostic Test: Air venous plethysmography; Diagnostic Test: Echocardiography; Diagnostic Test: Electrocardiogram; Diagnostic Test: Exercise Stress Transthoracic Echocardiogram; Diagnostic Test: Holter ECG; Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy; Diagnostic Test: Upper member arterial Doppler echography with analysis of FMD; Diltiazem; Diovan; Diovan 160 mg; Diovan 40 mg; Diovan 80 mg; Dobutamine; Echo and myocardial contrast echocardiography perfusion imaging; Eleclazine; Endothelial function biomarkers; Entresto; GS-6615 3 mg; GS-6615 3 mg Pink; GS-6615 3 mg White; GS-6615 6 mg; GS-6615 6 mg White; Gadolinium; Gradient; Gutron 2,5mg; Gutron 5mg; Hyperpolarized 13C-Pyruvate; LCZ696; LCZ696 100 mg; LCZ696 200 mg; LCZ696 50 mg; Losartan; Losartan Bluefish 50 mg; MAVACAMTEN; MEK162; MIDODRINE HYDROCHLORIDE; MONITOR; MYK-461; Mangafodipir; Mavacamten; Metoprolol; Metoprolol Succinate; Midodrine; N-acetylcysteine; Nitrate; Other: Exercise echocardiography; Other: Mangafodipir trisodium; Other: Walk distance test; Perhexiline; Perxexiline; Pexsig; Phosphorous; Piperazine; Pirfenidone; Procedure: 3D electrocardiographic mapping (ECM); Procedure: B-lines SE; Procedure: Coronary flow reserve SE; Procedure: Diastolic function SE; Procedure: Echocardiography (TEE); Procedure: Left ventricular contractile reserve SE; Procedure: Left ventricular outflow tract gradient SE; Procedure: Mitral regurgitation SE; Procedure: Pulmonary hemodynamics SE; Procedure: RF catheter ablation; Procedure: trans-right ventricular alcohol septal ablation (TRVASA); Pyrazole; RANEXA; RANEXA*60CPR 500MG R.P.; RANEXA*60CPR 750MG R.P.; RANOLAZINE; Ranexa; Ranolazine; Ranolazine 1000 mg PR tablets; Ranolazine 500 mg PR tablets; Ranolazine 750 mg PR tablets; Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die; Regadenoson; SACUBITRIL VALSARTAN; Sacubitril; Sacubitril/Valsartan; Sacubitril/valsartan; Sodium Nitrate; Sodium nitrate; Spironolactone; Treatment BX1514M; Trientine; Trientine Dihydrochloride; Trientine dihydrochloride; Triethylinetetramine dihydrochloride; Trimetazidine; Trimetazidine Dihydrochloride 20mg; Trimetazidine dihydrochloride; VALSARTAN; Valsartan; Vastarel; Vastarel 20mg film coated tablets; [MYK-461]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-002785-12-ES (EUCTR)	25/05/2020	20/12/2019	Pharmacokinetic and Pharmacodynamic study to evaluate the effect of CK-3773274 in patients with obstructive hypertrophic cardiomyopathy (oHCM)	A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction	obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE	Cytokinetics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	United States;Spain;Netherlands;United Kingdom;Italy
2	EUCTR2019-002785-12-GB (EUCTR)	08/05/2020	31/12/2019	Pharmacokinetic and Pharmacodynamic study to evaluate the effect of CK-3773274 in patients with obstructive hypertrophic cardiomyopathy (oHCM)	A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction	obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE	Cytokinetics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	United States;Spain;Netherlands;Italy;United Kingdom
3	NCT04219826 (ClinicalTrials.gov)	January 10, 2020	3/1/2020	REDWOOD-HCM: Randomized Evaluation of Dosing With CK-3773274 in Obstructive Outflow Disease in HCM	A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction	Obstructive Hypertrophic Cardiomyopathy	Drug: CK-3773274 (5 - 15 mg);Drug: CK-3773274 (10 - 30 mg);Drug: Placebo for CK-3773274	Cytokinetics	NULL	Recruiting	18 Years	85 Years	All	60	Phase 2	United States;Italy;Netherlands;Spain
4	NCT03767855 (ClinicalTrials.gov)	December 4, 2018	3/12/2018	A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects	A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multi-Part, Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects	Symptomatic Obstructive Hypertrophic Cardiomyopathy;Healthy Subjects	Drug: CK-3773274 - Granules in Capsule;Drug: Placebo - Granules in Capsule;Drug: CK-3773274 - Tablets	Cytokinetics	NULL	Completed	18 Years	55 Years	All	114	Phase 1	United States
5	EUCTR2019-002785-12-NL (EUCTR)		20/01/2020	Pharmacokinetic and Pharmacodynamic study to evaluate the effect of CK-3773274 in patients with obstructive hypertrophic cardiomyopathy (oHCM)	A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction	obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE	Cytokinetics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	United States;Spain;Netherlands;United Kingdom;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-002785-12-ES
(EUCTR)

25/05/2020

20/12/2019

Pharmacokinetic and Pharmacodynamic study to evaluate the effect of CK-3773274 in patients with obstructive hypertrophic cardiomyopathy (oHCM)

A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

obstructive hypertrophic cardiomyopathy (oHCM)
MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Product Code: CK-3773274
INN or Proposed INN: CK-3773274
Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
Product Code: CK-3773274
INN or Proposed INN: CK-3773274
Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
Product Code: CK-3773274
INN or Proposed INN: CK-3773274
Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
Product Code: CK-3773274
INN or Proposed INN: CK-3773274
Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE

Cytokinetics, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Spain;Netherlands;United Kingdom;Italy

EUCTR2019-002785-12-GB
(EUCTR)

08/05/2020

31/12/2019

Pharmacokinetic and Pharmacodynamic study to evaluate the effect of CK-3773274 in patients with obstructive hypertrophic cardiomyopathy (oHCM)

Cytokinetics, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Spain;Netherlands;Italy;United Kingdom

NCT04219826
(ClinicalTrials.gov)

January 10, 2020

3/1/2020

REDWOOD-HCM: Randomized Evaluation of Dosing With CK-3773274 in Obstructive Outflow Disease in HCM

A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Obstructive Hypertrophic Cardiomyopathy

Drug: CK-3773274 (5 - 15 mg);Drug: CK-3773274 (10 - 30 mg);Drug: Placebo for CK-3773274

Cytokinetics

NULL

Recruiting

18 Years

85 Years

All

Phase 2

United States;Italy;Netherlands;Spain

NCT03767855
(ClinicalTrials.gov)

December 4, 2018

3/12/2018

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multi-Part, Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Symptomatic Obstructive Hypertrophic Cardiomyopathy;Healthy Subjects

Drug: CK-3773274 - Granules in Capsule;Drug: Placebo - Granules in Capsule;Drug: CK-3773274 - Tablets

Cytokinetics

NULL

Completed

18 Years

55 Years

All

114

Phase 1

United States

EUCTR2019-002785-12-NL
(EUCTR)

20/01/2020

Pharmacokinetic and Pharmacodynamic study to evaluate the effect of CK-3773274 in patients with obstructive hypertrophic cardiomyopathy (oHCM)

Cytokinetics, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Spain;Netherlands;United Kingdom;Italy